Related Experiment Videos
Leiomyosarcoma of somatic soft tissues.
Henry J Mankin1, Jorge Casas-Ganem, Jeung-Il Kim
1Department of Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. hmankin@partners.org
Clinical Orthopaedics and Related Research
|May 5, 2004
Summary
Leiomyosarcoma, a rare smooth muscle cancer, frequently affects adults. Tumor size, stage, and location impact survival, with surgery and adjunctive agents showing better outcomes than surgery alone.
Area of Science:
- Oncology
- Pathology
Background:
- Leiomyosarcoma is a rare, aggressive malignant tumor originating from smooth muscle.
- It most commonly occurs in the uterus, bowel, and vascular tissues, but also in soft tissue and bone.
- Soft tissue leiomyosarcoma shares histologic features with myxofibrosarcoma.
Purpose of the Study:
- To review the clinical and prognostic features of leiomyosarcoma.
- To analyze factors influencing patient outcomes.
Main Methods:
- Retrospective review of 66 patients treated at an Orthopaedic Oncology Service.
- Analysis of prognostic factors including tumor size, MSTS stage, and anatomic site.
Main Results:
- Half of the patients died of disease within a mean of 3 years.
- Increased mortality was associated with larger tumor size, higher MSTS stage, and specific anatomic sites.
- Surgery combined with adjunctive agents correlated with improved survival compared to surgery alone.
Conclusions:
- Leiomyosarcoma presents significant mortality challenges.
- Prognosis is influenced by tumor characteristics and stage.
- Multimodal treatment strategies, including surgery and adjunctive agents, may improve survival outcomes.